[
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know",
    "summary": "In the most recent trading session, Gilead Sciences (GILD) closed at $113.24, indicating a +1.96% shift from the previous trading day.",
    "url": "https://finnhub.io/api/news?id=e621c91eb4795735c242853bc566f2ecb41dd30c881af3d3fedfdce96c2f5d6a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752098402,
      "headline": "Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know",
      "id": 135856177,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "In the most recent trading session, Gilead Sciences (GILD) closed at $113.24, indicating a +1.96% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=e621c91eb4795735c242853bc566f2ecb41dd30c881af3d3fedfdce96c2f5d6a"
    }
  },
  {
    "ts": null,
    "headline": "AHF: Gilead’s Greed Costs Latin America HIV Protection",
    "summary": "MEXICO CITY, July 09, 2025--AIDS Healthcare Foundation (AHF) denounces Gilead Sciences for once again excluding Latin America and the Caribbean (LAC) from affordable access to a groundbreaking HIV prevention drug, lenacapavir. Today’s announcement of a pricing and procurement deal between Gilead and the Global Fund to Fight AIDS, Tuberculosis and Malaria leaves most countries in the region out, forcing them to negotiate individually and in secrecy.",
    "url": "https://finnhub.io/api/news?id=eedfb136439c78441c7bec84fccdcfd2fd8637c79351e5cc94402fc99de76b25",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752093420,
      "headline": "AHF: Gilead’s Greed Costs Latin America HIV Protection",
      "id": 135856178,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "MEXICO CITY, July 09, 2025--AIDS Healthcare Foundation (AHF) denounces Gilead Sciences for once again excluding Latin America and the Caribbean (LAC) from affordable access to a groundbreaking HIV prevention drug, lenacapavir. Today’s announcement of a pricing and procurement deal between Gilead and the Global Fund to Fight AIDS, Tuberculosis and Malaria leaves most countries in the region out, forcing them to negotiate individually and in secrecy.",
      "url": "https://finnhub.io/api/news?id=eedfb136439c78441c7bec84fccdcfd2fd8637c79351e5cc94402fc99de76b25"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences (NasdaqGS:GILD) Partners With Global Fund To Supply HIV Prevention Drug",
    "summary": "Gilead Sciences (NasdaqGS:GILD) recently announced a partnership with the Global Fund to supply lenacapavir for HIV prevention, marking a significant client collaboration. This and other positive events, such as the FDA's approval of Yeztugo for PrEP and clinical trial successes, highlight the company's active engagement in expanding access and treatment options. These factors may have bolstered investor confidence, aligning with a broader market trend, which saw modest gains amid trade...",
    "url": "https://finnhub.io/api/news?id=dfd067beae76f6cb91dafeca11bc7487b72f1a56b32d141a9edc18fbc5f885d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752081631,
      "headline": "Gilead Sciences (NasdaqGS:GILD) Partners With Global Fund To Supply HIV Prevention Drug",
      "id": 135835991,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (NasdaqGS:GILD) recently announced a partnership with the Global Fund to supply lenacapavir for HIV prevention, marking a significant client collaboration. This and other positive events, such as the FDA's approval of Yeztugo for PrEP and clinical trial successes, highlight the company's active engagement in expanding access and treatment options. These factors may have bolstered investor confidence, aligning with a broader market trend, which saw modest gains amid trade...",
      "url": "https://finnhub.io/api/news?id=dfd067beae76f6cb91dafeca11bc7487b72f1a56b32d141a9edc18fbc5f885d0"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
    "summary": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=8dfd21c5a2c6cfb42c9b337e89b6b40a5a4f51d7dcd50cf5b8836df581365ea7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752079020,
      "headline": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
      "id": 135860589,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=8dfd21c5a2c6cfb42c9b337e89b6b40a5a4f51d7dcd50cf5b8836df581365ea7"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (GILD) Reports Advances in HIV Treatment with Phase 2/3 Clinical Trial Update",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio. Bridgewater Associates holds over $56 million worth of shares of GILD, which represents 0.26% of its portfolio. On June 26, 2025, Gilead Sciences, Inc. (NASDAQ:GILD) announced the development of its ongoing Phase 2/3 clinical trial that […]",
    "url": "https://finnhub.io/api/news?id=ace3ce96671020bc3bb6b053636158f23e7467ca1373fe9a57c9dea82c7a9aa2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752070475,
      "headline": "Gilead Sciences, Inc. (GILD) Reports Advances in HIV Treatment with Phase 2/3 Clinical Trial Update",
      "id": 135835992,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio. Bridgewater Associates holds over $56 million worth of shares of GILD, which represents 0.26% of its portfolio. On June 26, 2025, Gilead Sciences, Inc. (NASDAQ:GILD) announced the development of its ongoing Phase 2/3 clinical trial that […]",
      "url": "https://finnhub.io/api/news?id=ace3ce96671020bc3bb6b053636158f23e7467ca1373fe9a57c9dea82c7a9aa2"
    }
  },
  {
    "ts": null,
    "headline": "$14 Billion Cell and Gene Therapy Market to Double by 2030, Driven by Oncology and RNA Breakthroughs, reports Kalorama Information",
    "summary": "Kalorama Information, a leading authority in healthcare market research, announces the release of its new report, Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024–2030). The study reveals that the global market for cell and gene therapy (CGT) is poised to surge from $14.1 billion in 2024 to more than double by 2030, driven by scientific advancements, regional market expansion, and next-generation product approvals.",
    "url": "https://finnhub.io/api/news?id=c7ce7102ffc96cd886fd49e55871a9080999cd7e6f30b57bdc309c07bca85347",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752068940,
      "headline": "$14 Billion Cell and Gene Therapy Market to Double by 2030, Driven by Oncology and RNA Breakthroughs, reports Kalorama Information",
      "id": 135835994,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Kalorama Information, a leading authority in healthcare market research, announces the release of its new report, Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024–2030). The study reveals that the global market for cell and gene therapy (CGT) is poised to surge from $14.1 billion in 2024 to more than double by 2030, driven by scientific advancements, regional market expansion, and next-generation product approvals.",
      "url": "https://finnhub.io/api/news?id=c7ce7102ffc96cd886fd49e55871a9080999cd7e6f30b57bdc309c07bca85347"
    }
  },
  {
    "ts": null,
    "headline": "Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finnhub.io/api/news?id=6f28fc8b552a632cea56426847d3af60c71b11fcd3e716290ae282a5b51eba3b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752068403,
      "headline": "Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term",
      "id": 135835995,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
      "url": "https://finnhub.io/api/news?id=6f28fc8b552a632cea56426847d3af60c71b11fcd3e716290ae282a5b51eba3b"
    }
  },
  {
    "ts": null,
    "headline": "Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet",
    "summary": "Based on the average brokerage recommendation (ABR), Gilead (GILD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
    "url": "https://finnhub.io/api/news?id=7329e8e2068e02e96b9c5789519df0eaf98c1d4c2d4dfb9bd039bd395577d7e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752067803,
      "headline": "Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet",
      "id": 135835996,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Based on the average brokerage recommendation (ABR), Gilead (GILD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
      "url": "https://finnhub.io/api/news?id=7329e8e2068e02e96b9c5789519df0eaf98c1d4c2d4dfb9bd039bd395577d7e3"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries",
    "summary": "FOSTER CITY, Calif., July 09, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) to supply lenacapavir—Gilead's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). Through the agreement, Gilead will supply enough doses to reach up to two million people over three years in countries supported by the Global Fund, at no profit",
    "url": "https://finnhub.io/api/news?id=2e764af7416b9abe710a688f830a216bfaf057ad0ed8683ed34e53823cd31252",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752062400,
      "headline": "Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries",
      "id": 135835998,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., July 09, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) to supply lenacapavir—Gilead's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). Through the agreement, Gilead will supply enough doses to reach up to two million people over three years in countries supported by the Global Fund, at no profit",
      "url": "https://finnhub.io/api/news?id=2e764af7416b9abe710a688f830a216bfaf057ad0ed8683ed34e53823cd31252"
    }
  },
  {
    "ts": null,
    "headline": "Gilead finalizes agreement with global fund to accelerate access to Lenacapavir",
    "summary": "Gilead Sciences Inc: Gilead Sciences: agreement with global fund to accelerate access to Lenacapavir for HIV prevention in low-income countries Gilead Sciences: to provide Lenacapavir to 2...",
    "url": "https://finnhub.io/api/news?id=2052b532b8a3bf128e1b38899c32e8ec3aece8a5f81d0a8d5d75c82be6a336bf",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752057321,
      "headline": "Gilead finalizes agreement with global fund to accelerate access to Lenacapavir",
      "id": 135834383,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Gilead Sciences Inc: Gilead Sciences: agreement with global fund to accelerate access to Lenacapavir for HIV prevention in low-income countries Gilead Sciences: to provide Lenacapavir to 2...",
      "url": "https://finnhub.io/api/news?id=2052b532b8a3bf128e1b38899c32e8ec3aece8a5f81d0a8d5d75c82be6a336bf"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. Finalizes Agreement with the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for Up to Two Million People in Primarily Low- and Lower- Middle-Income Countries",
    "summary": "Gilead Sciences, Inc. announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir--Gilead's twice-yearly injectable HIV-1 capsid...",
    "url": "https://finnhub.io/api/news?id=c75c8f1e085149e4e72e19ab2cd3e9d4aef8d2d890c6ca92234fcede51b81639",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752051937,
      "headline": "Gilead Sciences, Inc. Finalizes Agreement with the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for Up to Two Million People in Primarily Low- and Lower- Middle-Income Countries",
      "id": 135833592,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Gilead Sciences, Inc. announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir--Gilead's twice-yearly injectable HIV-1 capsid...",
      "url": "https://finnhub.io/api/news?id=c75c8f1e085149e4e72e19ab2cd3e9d4aef8d2d890c6ca92234fcede51b81639"
    }
  },
  {
    "ts": null,
    "headline": "Gilead, Global Fund finalize plan to supply HIV prevention drug to poor countries",
    "summary": "Gilead Sciences and theGlobal Fund to Fight AIDS, Tuberculosis and Malaria said onWednesday they had finalized plans to supply a long-acting HIVprevention drug to low-income countries, despite the...",
    "url": "https://finnhub.io/api/news?id=c1713b900bdc4a648e809b85898937dcca8b01d9cd71047556f87648051db032",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752048094,
      "headline": "Gilead, Global Fund finalize plan to supply HIV prevention drug to poor countries",
      "id": 135833014,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Gilead Sciences and theGlobal Fund to Fight AIDS, Tuberculosis and Malaria said onWednesday they had finalized plans to supply a long-acting HIVprevention drug to low-income countries, despite the...",
      "url": "https://finnhub.io/api/news?id=c1713b900bdc4a648e809b85898937dcca8b01d9cd71047556f87648051db032"
    }
  }
]